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INTRODUCTION
Thyroid transcription factor-1 (TTF-1) is a 38-kDa home-
odomain containing DNA-binding protein of the Nkx-2 gene
family, which is expressed in the thyroid, lungs, and some re-
stricted areas of diencephalon (1). During human development,
it appears in early stages and thus could play an important role
in cell differentiation and morphogenesis of both the thyroid
and lung (1). TTF-1 activates transcription of thyroglobulin
and thyroperoxidase genes in the follicular thyroid cells, but
not in lung epithelial cells (2-5). Conversely, the role of TTF-1
in lung tissues involves regulation of the surfactant and Clara
cell secretory protein gene expression, but not in follicular thy-
roid cells (6-8).
Since the expression of TTF-1 is an early event during lung
differentiation, the evaluation of TTF-1 expression in lung
tumors may have an impact in clinical research and in the man-
agement of these neoplasms (9). Also, tissue-specific transcrip-
tion factors contribute to the transcriptional activation of genes
expressed in particular cell types, and thus the study of tran-
scription factors like TTF-1 in human lung tumors could be
of benefit in our understanding of the molecular events of their
neoplastic transformation (10, 11).
In lung cancers, several reports described the differences in
TTF-1 expression between histologic types (11-17). They re-
ported that TTF-1 was expressed in 62.5-90% of adenocarci-
nomas and 89-100% of small cell carcinoms, whereas it was
not found or found at a very low frequency in squamous car-
cinomas (0-27%) and large cell carcinomas (0-25%). Most re-
ports have emphasized the usefulness of TTF-1 in differential
diagnosis of lung cancer from nonpulmonary cancers, where-
as relatively few and contradictory data are available on the
prognostic implication of TTF-1 immunoreactivity because
its upregulation has been considered as a favorable or unfa-
vorable predictor of survival in patients with non-small cell
lung carcinoma (NSCLCs) (13, 14, 16, 18). Also, there are
few studies referred to possible significance of TTF-1 expres-
sion in lung carcinogenesis, despite its crucial roles in lung
development and maintenance of pulmonary function by means
of surfactant apoprotein A and Clara cell antigen induction.
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Thyroid Transcription Factor-1 (TTF-1) Expression in Human Lung
Carcinomas: Its Prognostic Implication and Relationship with 
Expressions of p53 and Ki-67 Proteins
This study was aimed to evaluate the prevalence and prognostic implication of thy-
roid transcription factor-1 (TTF-1) immunoreactivity in 81 human lung carcinomas,
including 65 cases of non-small cell lung carcinoma (NSCLC) and 16 cases of small
cell lung carcinoma (SCLC); and also to investigate its relationship with the cell pro-
liferation and regulation by immunostaining of Ki-67 and p53 proteins, respectively.
The immunohistochemical staining for TTF-1 (clone 8G7G3/1) was performed and
several clinicopathologic variables and the follow-up data were obtained. The immuno-
staining results for TTF-1 were semiquantitatively interpreted as negative and pos-
itive. Of NSCLCs, TTF-1 is highly expressed in adenocarcinomas (76%), whereas
squamous cell carcinomas revealed no immunoreactivity (0%). SCLCs showed strong
TTF-1 expression (88%). In NSCLC, TTF-1 expression was inversely correlated with
Ki-67 proliferative activity and independent of p53 overexpression. TTF-1 (+) group
tended to show better survival than TTF-1 (-) group in NSCLC. Conclusively, these
observations suggest that TTF-1 is a sensitive and specific diagnostic marker for
pulmonary adenocarcinomas and SCLCs; that TTF-1 might have a good prognostic
implication based on its inverse correlation with Ki-67 proliferative activity and ten-
dency for better survival in NSCLC; that this cell lineage marker may play a role in
the molecular pathogenesis of lung cancers at the level of transcription.
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Other factors for risk stratification in patients with lung
cancers include the tumor proliferative potential, which is com-
monly evaluated by Ki-67 antigen immunostaining, and the
mutation in p53 genes, the most common genetic alteration
in lung cancers (14, 15, 18). Although the independent pro-
gnostic role of these prognostic factors in lung cancer patients
still remains a matter of debate, there are no doubts the cell
proliferation and the regulation of cell cycle are essential fac-
tors for tumor growth. However, the relationships between
TTF-1 and cell proliferation or p53 overexpression have been
only rarely reported in human lung carcinomas, including
NSCLC and small cell lung carcinoma (SCLC) (14, 15, 18).
This study was aimed at evaluating the prevalence and pro-
gnostic implication of TTF-1 immunoreactivity in 65 cases
of NSCLC and 16 cases of SCLC patients, and at demonstrat-
ing its relationship with cell proliferation assesed by Ki-67
immunostaining and cell-cycle regulation by p53 staining.
Our findings indicate that TTF-1 is expressed almost exclu-
sively by adenocarcinomas and small cell carcinomas, and thus
this transcriptional protein is likely to be involved in the growth
of adenocarcinomas and small cell carcinomas, with inverse
correlation with Ki-67 proliferative potential; and that TTF-1
immunoreactive NSCLCs show a trend for a favorable clinical
course, although the TTF-1 immunoreactivity fails to con-
firm a statistically significant prognostic implication.
MATERIALS AND METHODS
Patients and tissue samples
Primary tumor specimens from 65 NSCLCs and 16 SCLCs
were obtained by surgical resection and bronchoscopic biopsy,
respectively, between 1996 and 2001 at the Dankook Univer-
sity Hospital. All hematoxylin-eosin stained slides of the tis-
sue samples were reviewed, and the pathological diagnoses of
the histologic grades and types were confirmed by a pathol-
ogist. Histologic typing was performed according to the World
Health Organization diagnostic criteria for lung carcinomas
(1999). The hospital records of all 81 patients (65 NSCLCs
and 16 SCLCs) were reviewed to obtain the clinicopathologic
variables such as age, sex, smoking history, tumor-node-metas-
tasis (TNM) stage (in NSCLC), and tumor extent (in SCLC).
The pathologic staging of NSCLC and SCLC was assessed ac-
cording to the TNM Classification of AJCC staging system
(1997), and the Veterans’ Administration Lung Study Group
(VALSG) staging system (1973), respectively. Death from lung
cancer was the terminal event for survival calculations. All
patients were followed for up to about 5 yr.
Immunohistochemical analysis
All specimens used in this study were 4  m-thick sections
of paraffin-embedded tissue obtained at surgery and broncho-
scopic biopsy. The standard avidin-biotin-peroxidase complex
method was used for immunohistochemical examination using
monoclonal antibodies against TTF-1 (8G7G3/1, NeoMark-
ers, CA, U.S.A.), p53 (DO7, Novocastra, Newcastle-upon-
Tyne, U.K.), Ki-67 (AO47, DAKO, Carpinteria, CA, U.S.A.).
Deparaffinization of all sections were performed through a
series of xylene baths, and rehydration was performed through
graded ethyl alcohols. The sections were microwaved in 10 mM
citrate buffer at 90℃ for 10 min, and were treated with 3%
H2O2-PBS solution to reduce endogenous peroxidase activi-
ty. Then, they were incubated with normal bovine serum to
reduce nonspecific antibody binding and were subsequently
subjected to the primry antibody reactions. The antibodies for
TTF-1, p53, and Ki-67 proteins were reacted with the sections
at room temperature for one hour at the same dilution (1:100).
Detection of the immunoreactive staining was carried out by
avidin-biotin-peroxidase complex method using the LSAB
kit (DAKO). The sections were subjected to a color reaction
with 3,3-diaminobenzidine tetrahydrochloride containing 3%
H2O2 in Tris buffer, and were lightly counterstained with Ma-
yer’ s hematoxylin.
For evaluation of the expressions of TTF-1, p53, and Ki-67
proteins, the immunostained cells were considered positive
only when distinct nuclear staining was identified. The extent
of the positive cells was semiquantitatively scored as follows:
0, negative reaction; 1, <5% positive tumor cells; 2, 5-50%;
3, 51-100% of tumor cells. The staining intensity was eval-
uated with three categorized scores of weak 1, moderate 2, and
strong 3. To exclude equivocal reactions, the staining was re-
garded as positive for TTF-1 expression when the combined
scores were more than 2 (≥2). Cases were considered positive
for Ki-67 expression, when more than 10% of tumor cells were
reactive, because the median value of Ki-67 proliferative frac-
tion was about 10% in all cases. Cases were considered posi-
tive for p53 overexpression, when at least 50% of tumor cells
showed nuclear immunopositivity because high p53 expres-
sion would be expected if p53 mutations existed (19). To obtain
the survival curves, the TTF-1 nuclear staining was divided
into as negative (scores 0-1) and positive (scores 2-9) groups
based on the tumor nuclei with unequivocal staining.
Statistical Analysis
The comparison of TTF-1 immunoreactivity between sev-
eral two-categorical clinicopathologic variables and the rela-
tionships of TTF-1 expression with Ki-67 proliferative activ-
ity and p53 overexpression were analysed by chi-square test
(SPSS 10.0). The survival period was calculated as the time
from the date of surgery to the date of death or last follow-up.
Postoperative survival curves were constructed using the Ka-
plan-Meier method and then compared by the log rank test.
A pvalue less than 0.05 was defined as statistically significant.496 N.-H. Myong
RESULTS
Clinicopathologic data and correlation with TTF-1
expression
Patient profiles are shown in Tables 1 and 2. NSCLC group
consisted of 49 men and 16 women, with median ages of 58.0
and 61.8 yr, respectively. The SCLC group included 14 men
and 2 women with median ages of 60.6 and 62 yr, respective-
ly. Overall, the median age at diagnosis was 59.9 yr (range:
31-83) in NSCLC and 60.8 yr in SCLC (range: 38-75). All 16
SCLC patients were smokers. The pathological staging of
the 65 NSCLC cases revealed 25 cases of stage 1, 10 of stage
2, and 30 of stage 3. Pathological T stages were pT1 in 14
cases, pT2 in 31, pT3 in 16, and pT4 in 4. The 16 SCLC
cases were staged as 8 limited and 8 extensive diseases. The
histologic types of 65 NSCLCs included 30 cases of squamous
cell carcinoma (SCC), 25 cases of adenocarcinoma (ADC), 3
cases of adenosquamous carcinoma (ASC), 2 cases of bronchi-
oloalveolar carcinoma (BAC), 3 cases of large cell carcinoma
(LCC), and 2 cases of pleomorphic carcinoma (PLC), based on
the WHO classification (1999). The adenocarcinomas and sq-
uamous cell carcinomas were graded as 6 cases of grade 1 (well
differentiated), 36 of grade 2 (moderately differentiated), and
13 of grade 3 (poorly differentiated). Clinicopathologic vari-
ables such as age, smoking history, tumor size, and histolog-
ic grades in NSCLCs were not significantly associated with
TTF-1 expression, although TTF-1 expression tend to be
higher in non- smokers and well-differentiated tumors. How-
ever, TTF-1 was expressed significantly higher in women than
in men (p<0.05) and in ADCs than SCCs (p<0.001).
In SCLCs, any significant difference in TTF-1 expression
was not found between two categorical groups of the clinco-
pathologic variables such as age, sex, and stage.
TTF-1 expression in normal lung, NSCLCs, and SCLCs
In non-neoplastic lung, nuclear TTF-1 immunoreactivity
was limited in alveolar and bronchiolar epithelial cells; inter-
stitial cells, lymphocytes, alveolar macrophages did not stain
for TTF-1 (Fig. 1). No differences between non-neoplastic and
malignant cells were observed in the staining pattern with
TTF-1 antibody.
Overall, TTF-1 immunoreactivity was found in 23 (35%)
of 65 NSCLCs, including 19 (76%) of 25 ADCs, 1 (33%) of
3 ASCs, 1 (50%) of 2 BACs, 1 (33%) of 3 LCCs, and 1 (50%)
of 2 PLCs. The 30 squamous cell carcinomas were complete-
ly devoid of TTF-1 immunoreactivity (0%). No differences
in the nuclear immunoreactivity were noted among the dif-
ferent tumor types, and there was no preferential distribution
of TTF-1-reactive cells in perivascular, central, or peripheral
viable areas of the neoplasms. Among the different histolog-
ic types of NSCLCs, ADCs showed TTF-1 expression in the
majority of the cases (76%), which was significantly higher
than SCCs (0%) (p<0.001) (Fig. 2). TTF-1 expression did not
vary with the morphologic subtypes of ADCs, which showed
acinar and solid patterns. One of two BACs revealed TTF-1
*chi-square test, 
� : p value between the percentages of TTF-1 immunore-
activity in squamous cell carcinoma versus adenocarcinoma, SCC: squa-
mous cell carcinoma, ADC: adenocarcinoma, ASC: adenosquamous car-
cinoma, BAC: bronchioloalveolar carcinoma, LCC: large cell carcinoma,
PLC: pleomorphic carcinoma.
Clinicopathologic
features
No. of
cases
TTF-1 immunoreactivity
Positive (%) Negative (%)
p value*
Age 
≤59 yr 29 9 (31) 20 (72) 0.510
>59 yr 36 14 (42) 22 (58)
Sex
Male 49 14 (29) 35 (71) 0.044
Female 16 9 (56) 7 (44)
Smoking history
Smokers 48 14 (29) 34 (71) 0.078
Non-smokers 17 9 (53) 8 (47)
Stage
1 25 10 (40) 15 (60) 0.538
2-3 40 13 (33) 27 (67)
pT
1-2 45 17 (38) 28 (62) 0.545
3-4 20 6 (30) 14 (70)
Grade
1-2 42 17 (40) 25 (60) 0.096
3 13 2 (15) 11 (85)
Histologic type
SCC 30 0 (0) 30 (100) 0.000
�
ADC 25 19 (76) 6 (24)
ASC 3 1 (33) 2 (67)
BAC 2 1 (50) 1 (50)
LCC 3 1 (33) 2 (67)
PLC 2 1 (50) 1 (50)
Total 65 23 (35) 42 (65)
Table 1. Correlations between TTF-1 expression and clinico-
pathologic features in non-small cell lung carcinomas
*chi-square test, 
� 16 cases of SCLC were staged as limited and exten-
sive diseases.
Clinicopathologic
features
No. of
cases
TTF-1 immunoreactivity
Positive (%) Negative (%)
p value*
Age
≤59 yr 7 6 (86) 1 (14) 0.849
>59 yr 9 8 (89) 1 (11)
Sex
Male 14 12 (86) 2 (14) 0.568
Female 2 2 (100) 0 (0)
Stage
�
Limited disease 8 8 (100) 0 (0) 0.131
Extensive disease 8 6 (75) 2 (25)
Total 16 14 (88) 2 (12)
Table 2. Correlation between TTF-1 immunoreactivity and clini-
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expression not in mucinous type but in the non-mucinous
type (Fig. 3).
SCLCs examined in this study showed high frequency of
TTF-1 expression (88%), which was higher than adenocarci-
nomas (76%) (Fig. 4).
Association of TTF-1 expression with p53 and Ki-67
proteins in 65 NSCLCs
The statistical analysis for the relationships was shown in
Tables 3 and 4. Significant inverse correlation was found be-
tween TTF-1 expression and proliferative activity evaluated
by Ki-67 protein (p<0.01). However, there was no significant
Fig. 3. A bronchioloalveolar carcinoma of non-mucinous type re-
vealed high immunoreactivity for thyroid transcription factor-1 (TTF-
1) (×200).
Fig. 4. Pulmonary small cell carcinoma showing high nuclear ex-
pression for thyroid transcription factor-1 (TTF-1) (×400).
Fig. 1. Nuclear immunoreactivity for thyroid transcription factor-1
(TTF-1) in normal alveolar (A) and bronchiolar (B) epithelial cells
(×400).
A B
Fig. 2. Immunohistochemical finding of thyroid transcription factor-
1 (TTF-1) in moderately differentiated adenocarcinoma, showing
diffuse and strong nuclear immunoreactivity for TTF-1 (×400).498 N.-H. Myong
correlation between TTF-1 expression and the overexpression
of p53 protein, a cell cycle regulator. Two representative cases
are shown for the immunostaining results for Ki-67 prolif-
erative activity and p53 overexpression in Fig. 5.
Due to the small number of cases, those relationships were
not analyzed in 16 SCLCs.
Survival data and its comparison between TTF-1 (+)
and TTF-1 (-) groups
Complete follow-up information was available on 36 pati-
ents of 65 NSCLCs and 6 of 16 SCLCs, with a median follow-
up duration of 29.7 months for living patients (range 12-66
months) in NSCLCs and 45 (range 24-66 months) in SCLCs.
At the time of analysis, 26 (72.2%) and 2 (33%) patients were
alive in NSCLCs and SCLCs, respectively. When all of 65
NSCLC patients analyzed for postsurgical survival were exam-
ined for the difference in survival time between TTF-1 (+) and
TTF-1 (-) groups by Kaplan-Meier method and then log rank
test, the group with a positive immunoreactivity for TTF-1
tended to reveal the better survival, compared with the group
with a negative immunostaining for that (Fig. 6). When we
also obtained the survival curves for the lower (stage 1, 2) and
higher stage (stage 3) and compared them by log rank test, the
patients with stage 3 revealed significantly lower survival time
compared with those with stage 1, 2 (p=0.0077) (data not
shown).
Due to the limited number of SCLC patients, the statistical
analysis for the survival data between TTF-1 (+) and TTF-1
(-) groups was not performed.
DISCUSSION
Tissue-specific gene expression is mediated largely by tran-
scritional factors, and a master regulatory gene is thus a poten-
tial marker of cellular lineage (15, 20). TTF-1 is an example
of such a lineage marker, which plays a crucial role in normal
peripheral lung function and morphogenesis (15).
In the present study, normal lung tissue revealed a very lim-
ited expression for TTF-1 in the terminal airways such as alveol-
ar and bronchiolar epithelial cells. The staining was quite uni-
form, and TTF-1 appeared to be useful for labeling the com-
mited cells or lineage of the terminal respiratory unit. This
result also indicates that TTF-1 could be used as a molecular
marker of differentiation for neoplasms arising from these cell
Fig. 5. A case of squamous cell carcinoma showing moderately
brisk mitotic activity evaluated by Ki-67 immunostaining (A, ×400)
and diffuse nuclear immunopositivity for p53 protein (B, ×200).
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Fig. 6. Kaplan-Meier survival curves of patients with non-small cell
lung carcinoma (NSCLC). Comparison between TTF-1 positive and
TTF-1 negative groups shows a tendency for better survival in the
TTF-1 positive group (log rank test; p=0.0956).
*: chi-square test.
TTF-1 expression
No. of
cases
Ki-67 immunoreactivity
Positive (%) Negative (%)
p value*
Positive 23 9 (39) 14 (61) 0.003
Negative 42 32 (76) 10 (24)
*: chi-square test.
TTF-1 expression
No. of
cases
p53 overexpression
Positive (%) Negative (%)
p value*
Positive 23 10 (43) 13 (57) 0.215
Negative 42 25 (60) 17 (40)
Table 3. Correlation between TTF-1 expression and Ki-67 pro-
liferative activity in non-small cell lung carcinomas
Table 4. Correlation between TTF-1 expression and p53 over-
expression in non-small cell lung carcinomasTTF-1 Expression in Lung Carcinomas 499
types (9).
In the lung cancer group, TTF-1 expression was found in
23 NSCLCs of non-squamous cell type (35%) and 14 SCLCs
(88%). Of the 23 NSCLCs, the majority (19 cases, 83%) was
ordinary type of adenocarcinoma and the remaining consisted
of 1 non-mucinous type of BAC, 1 ASC, 1 LCC, and 1 PLC.
In a recent report (15), adenocarcinomas with terminal res-
piratory unit (TRU) morphology revealed significantly high-
er TTF-1 expression than those with non-TRU morphology.
They suggested that TTF-1 expression could be used as a lin-
eage marker for TRU type adenocarcinomas, and could play
a role in the molecular pathogenesis of those adenocarcino-
mas. Although the adenocarcinomas were not classified into
TRU and non-TRU type, the present study also suggested
that TTF-1 could be a useful marker of adenocarcinomas in
the diagnosis of poorly differentiated NSCLCs because there
was a highly significant difference in TTF-1 expression between
two major groups of NSCLCs, ADC and SCC (76% versus
0%, p=0.000). Also, TTF-1 expression in this study was sig-
nificantly higher in the female than in male, and tend to be
higher in non-smokers than in smokers. These results seem
to be associated with the fact that pulmonary ADCs tend to
be more prevalent in female non-smokers than SCCs. In our
study, all 30 cases of SCCs revealed no TTF-1 immunoreac-
tivity (0%). The rare occurrence or lack of TTF-1 immunore-
activity in SCC or metaplastic epithelium suggests that this
protein is not involved in the differentiation of squamous cells.
This fact is supported by a few studies showing that the lung-
specific genes activated by TTF-1 are not expressed in SCCs
(8, 17, 21). Pelosi et al. (14) also proposed a possibility of the
synthesized TTF-1 with an aberrant function in SCCs.
SCLC has also been reported to express TTF-1 in most cases
(89-100%) (9, 11, 12, 22), and our data confirmed the high
frequency of TTF-1 expression in SCLC (14 of 16, 88%). Al-
though this high frequency of TTF-1 expression in SCLC ap-
pears to conflict with the previously mentioned usefulness of
TTF-1 as the cell lineage marker for adenocarcinoma, Yatabe
et al. (15) explained it as follows; first, small cell carcinomas
frequently produce TTF-1 aberrantly like ectopic hormones;
second, SCLC is a type of neuroendocrine carcinoma and can
make TTF-1 because TTF-1 is reported to be expressed in
the the diencephalon area (1); and third, TTF-1 expression
may be atavistic in these undifferentiated cells of SCLC.
Taken together, the present study suggests that TTF-1 may
play an important role as the transcriptional factor in the molec-
ular pathogenesis of adenocarcinomas and small cell carcinomas.
Most of the previous studies on TTF-1 expression focused
on its usefulness as the immunohistochemical marker for diag-
nosis of lung tumors and for differential diagnosis of primary
pulmonary adenocarcinomas from extrapulmonary adenocar-
cinomas metastatic to the lung (23). Few studies investigated
the prognostic role of TTF-1 in NSCLC and showed contra-
dictory data on the relationship between TTF-1 expression
and survival (13, 14, 16, 18). In the current study, we found
that the patients with TTF-1 expression tend to survive longer
than TTF-1 (-) group, although the difference was not statis-
tically significant (log rank test, p=0.096). Potential sources
of the conflicting results of TTF-1 expression and survival in
the literatures have been analyzed, including the scoring sys-
tem of immunohistochemical staining for TTF-1, the stain-
ing procedure, and statistical analysis of data (14, 16).
Although the independent prognostic role of p53 mutation
and Ki-67 proliferative activity is still debatable in NSCLC,
the importance of p53 mutation and cell proliferation in the
pulmonary carcinogenesis seems to be obvious (14, 24). p53
is considered as the cell cycle regulator as it blocks progression
through the cell cycle in cells that have sustained DNA dam-
age (24). In general, p53 mutation or overexpression is con-
sidered as an indicator of poor prognosis. Also, Ki-67 is fre-
quently used to evaluate the prognostic value of proliferative
activity of lung cancers, and high Ki-67 expression was hypothe-
sized to be correlated with a poor clinical outcome (25). How-
ever, the study on the relationship between TTF-1 expression
and p53 overexpression or proliferative activity is very rare.
Yatabe et al. (15) reported that p53 overexpression showed
the negative correlation with TTF-1-positive adenocarcinoma.
Puglisi et al. (18) performed a combined analysis of TTF-1
and MIB-1 proliferative activity in NSCLCs, showing no cor-
relation between them but the poorest survival in the TTF-
1-positive/MIB-1-positive group. The presence of a relation-
ship between TTF-1 expression and cell proliferation has been
reported on the basis of data showing that reduced prolifer-
ation rate of thyroid cells is induced by decrease in TTF-1
concentration by antisense procedures (26). Also, it has been
suggested that homeodomain-containing nuclear proteins
functionally similar to TTF-1 have positive effects on cell
growth (27) as well as antiapoptotic effects demonstrated by
loss of function experiment (28).
However, our data unexpectedly showed inverse relationship
between the TTF-1 expression and Ki-67 proliferative activ-
ity in NSCLCs. This contradictory result seems to be difficult
to be interpreted because of paucity of the similar study except
for a study by Pelosi et al. (14). The investigation showed TTF-
1 immunoreactivity correlated inversely with the tumor pro-
liferative fraction assessed by Ki-67 immunostaining. But as
an interpretation for the result, they commented only that the
relationship of TTF-1 expression with cell proliferation of lung
cancer remains to be unveiled. Therefore, our result for the
inverse relationship between TTF-1 and proliferative activity
in NSCLCs remains to be proved further.
In conclusion, we confirmed that TTF-1 appears to be a rea-
sonably sensitive and highly specific diagnostic marker for pul-
monary adenocarcinomas and small cell carcinomas; that TTF-
1 may be used a good prognostic marker based on its negative
correlation with Ki-67 proliferative activity and tendency for
better survival; that the cell lineage marker of the lung may
in part participate in the molecular pathogenesis of lung can-
cers at the level of transcription.500 N.-H. Myong
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